Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EVEREST trial: what clinicians have said so far
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
- NCT01120249 ↗
- Completed
- SWOG Cancer Research Network
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on EVEREST yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EVEREST so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Kidney Cancer
- Interventions
- everolimus; placebo
- Arms
- Arm I · Experimental
- Arm II · Placebo comparator
- Enrollment
- 1,545
- Primary outcomes
- 5-year Recurrence-free Survival (RFS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Apr 1, 2011
- Primary completion
- Jul 1, 2023
- Results posted
- Yes
- Registry record
- NCT01120249 · updated Sep 16, 2025
Publications
linked from the registry- Gulati S, Tangen C, Ryan CW, Vaishampayan UN, Shuch BM, Barata PC, Pruthi DK, Bergerot CD, Tripathi A, Lerner SP, Thompson IM Jr, Lara PN Jr, Pal SK. Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Aug 1;7(8):e2425288. doi: 10.1001/jamanetworkopen.2024.25288. PubMed 39106067
- Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28. PubMed 37524096